Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

EULAR & ACR Define Rheumatic & Musculoskeletal Disease for Laymen

Thomas R. Collins  |  Issue: July 2018  |  July 19, 2018

The number of practicing rheuma­tologists varies greatly by region in the U.S., they wrote. There can be more than two rheumatologists per 100,000 people in highly populated areas, but in more rural regions, it can drop to as low as 1.5 rheumatologists per 1 million people. The numbers are falling, and shortages are expected to worsen, to 0.5 to 1.0 rheumatologist per 100,000 people in a large majority of the U.S. expected by 2025.

They say they hope the guidance serves a dual purpose: helping communicate the need for more research, given that effective treatments are unavailable for so many disorders, and helping patients have ready access to treatments made available with recent advances.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“We hope the description of RMDs provided in this report will enable improved communication about and advocacy for these conditions and the patients who suffer from them,” wrote Dr. van der Heijde and her colleagues.


Thomas R. Collins is a freelance writer living in South Florida.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. van der Heijde D, Daikh DI, Betterdidge N, et al. Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers, and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). Arthritis Rheumatol. 2018 Jun;70(6):826–831.
  2. van der Heijde D, Daikh DI, Betteridge N, et al. Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). Ann Rheum Dis. 2018 Jun;77(6):829–832.
  3. Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011 Mar;63(3):633–639.
  4. Musculoskeletal health in Europe report v5.0. EUMUSC.net. (n.d.).
  5. Jafarzadeh SR, Felson DT. Updated estimates suggest a much higher prevalence of arthritis in United States adults than previous ones. Arthritis Rheumatol. 2018 Feb;70(2):185–192.
  6. Mathers C, Stevens G, Mascarenhas M. Global health risks: Mortality and burden of disease attributable to selected major risks. Geneva: World Health Organization/WHO Press; 2009.

Page: 1 2 3 | Single Page
Share: 

Filed under:Professional Topics Tagged with:Media

Related Articles

    Désirée Van Der Heijde, MD, PhD, a Key Driver of Treatment Advances

    May 8, 2012

    Dr. van der Heijde learned early in her career that serendipity often plays a role in clinical research and treatment advances.

    “A Common Language for Spondyloarthritis”

    December 1, 2010

    ASAS fills a niche, changes dogma with consensus approach

    ACR/ARHP Annual Meeting 2012: Spondylarthritis Criteria Changing Landscape of the Disease

    December 1, 2012

    More finely tuned view of ankylosing spondylitis leads to better treatment, expert says

    To Measure is to Know

    October 1, 2007

    Piet van Riel, MD, PhD, shepherd of RA improvement criteria

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences